Skip to main content
Article
Plasma Krebs Cycle Intermediates in Nonalcoholic Fatty Liver Disease
Journal of Clinical Medicine
  • Yana Sandlers, Cleveland State University
  • Rohan R. Shah, Cleveland State University
  • Ryan W. Pearce, Cleveland State University
  • Jaividhya Dasarathy, Case Western Reserve University
  • Arthur J. McCullough, Cleveland Clinic Lerner Research Institute
  • Srinivasan Dasarathy, Cleveland Clinic Learner Research Institute
Document Type
Article
Publication Date
2-1-2020
Disciplines
Abstract

Nonalcoholic liver disease (NAFLD) is manifested with a wide spectrum of clinical symptoms and is closely associated with the metabolic syndrome, inflammation, and mitochondrial dysfunction. Although the mechanism of mitochondrial dysfunction in NAFLD is still not fully elucidated, multiple studies have demonstrated evidence of molecular, biochemical, and biophysical mitochondrial abnormalities in NAFLD. Given the association between NAFLD and mitochondrial dysfunction, the aim of this study is to analyze circulating levels of Krebs cycle intermediates in a cohort of NAFLD-affected individuals and matching healthy controls and to correlate our findings with the liver function metrics. Standard serum biochemistry and Krebs cycle intermediates were analyzed in NAFLD (n = 22) and matched control (n = 67) cohorts. Circulating levels of isocitrate and citrate were significantly (p < 0.05) elevated in the NAFLD cohort of patients. The area under the curve (AUROC) for these two metabolites exhibited a moderate clinical utility. Correlations between plasma Krebs cycle intermediates and standard clinical plasma metrics were explored by Pearson’s correlation coefficient. The data obtained for plasma Krebs cycle intermediates suggest pathophysiological insights that link mitochondrial dysfunction with NAFLD. Our findings reveal that plasma isocitrate and citrate can discriminate between normal and NAFLD cohorts and can be utilized as noninvasive markers of mitochondrial dysfunction in NAFLD. Future studies with large populations at different NAFLD stages are warranted.

Comments

Funded in part by: R21 AR 071045 (S.D.), R21 AA022742 (S.D.); RO1 GM119174; RO1 DK113196 (S.D.); P50 AA024333 (S.D.); UO1 AA021890 (S.D.); UO1 DK 061732-17, Mikati Foundation (G.D., S.D.) and Cleveland State University startup funds (Y.S.).

Creative Commons License
Creative Commons Attribution 4.0 International
DOI
10.3390/jcm9020314
Version
Publisher's PDF
Citation Information
Yana Sandlers, Rohan R. Shah, Ryan W. Pearce, Jaividhya Dasarathy, et al.. "Plasma Krebs Cycle Intermediates in Nonalcoholic Fatty Liver Disease" Journal of Clinical Medicine Vol. 9 Iss. 2 (2020)
Available at: http://works.bepress.com/yana-sandlers/22/